Evotec (EVO) Competitors $4.02 +0.04 (+1.01%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.01 -0.01 (-0.25%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. TGTX, NUVL, CRSP, RYTM, LNTH, AXSM, TLX, PCVX, MRUS, and CYTKShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Axsome Therapeutics Telix Pharmaceuticals Vaxcyte Merus Cytokinetics Evotec (NASDAQ:EVO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation. Do institutionals & insiders believe in EVO or TGTX? 5.8% of Evotec shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 10.6% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, EVO or TGTX? Evotec has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Which has preferable earnings and valuation, EVO or TGTX? TG Therapeutics has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.66-$212.18MN/AN/ATG Therapeutics$329M16.90$23.38M$0.24145.92 Do analysts prefer EVO or TGTX? Evotec presently has a consensus price target of $5.90, indicating a potential upside of 46.77%. TG Therapeutics has a consensus price target of $43.80, indicating a potential upside of 25.07%. Given Evotec's higher possible upside, equities analysts clearly believe Evotec is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is EVO or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to Evotec's net margin of -26.34%. TG Therapeutics' return on equity of 18.88% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% TG Therapeutics 10.13%18.88%7.05% Does the media refer more to EVO or TGTX? In the previous week, TG Therapeutics had 11 more articles in the media than Evotec. MarketBeat recorded 12 mentions for TG Therapeutics and 1 mentions for Evotec. TG Therapeutics' average media sentiment score of 1.14 beat Evotec's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTG Therapeutics beats Evotec on 12 of the 14 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E RatioN/A8.9728.7823.81Price / Sales1.66437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book1.384.838.275.54Net Income-$212.18M$31.62M$3.25B$259.28M7 Day Performance-5.63%-5.28%-3.70%-4.64%1 Month Performance-7.37%4.38%4.34%4.41%1 Year Performance-9.05%-2.49%25.90%17.95% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.764 of 5 stars$4.02+1.0%$5.90+46.8%-13.2%$1.41B$862.40M0.004,827News CoverageTGTXTG Therapeutics4.0794 of 5 stars$35.99-2.5%$43.80+21.7%+85.0%$5.86B$329M149.96290Positive NewsUpcoming EarningsNUVLNuvalent3.2323 of 5 stars$81.94+0.7%$119.60+46.0%+2.0%$5.85BN/A-18.6740Positive NewsCRSPCRISPR Therapeutics2.8206 of 5 stars$63.75-1.6%$71.31+11.9%+2.3%$5.59B$37.31M-14.10460Upcoming EarningsAnalyst RevisionGap DownRYTMRhythm Pharmaceuticals3.5511 of 5 stars$85.68-0.9%$91.93+7.3%+88.5%$5.50B$130.13M-30.49140Upcoming EarningsInsider TradeLNTHLantheus4.6193 of 5 stars$72.41-0.7%$131.20+81.2%-28.4%$5.05B$1.53B20.57700News CoveragePositive NewsUpcoming EarningsAnalyst RevisionAXSMAxsome Therapeutics4.8236 of 5 stars$100.39-0.4%$172.33+71.7%+19.8%$4.96B$385.69M-17.40380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.81B$516.72M0.00N/AGap DownPCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.73BN/A-8.99160News CoveragePositive NewsUpcoming EarningsMRUSMerus2.9208 of 5 stars$65.59-1.8%$86.40+31.7%+25.1%$4.62B$36.13M-16.0837News CoverageUpcoming EarningsCYTKCytokinetics4.0943 of 5 stars$36.63-1.5%$70.92+93.6%-36.6%$4.44B$18.47M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies TG Therapeutics Alternatives Nuvalent Alternatives CRISPR Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives Vaxcyte Alternatives Merus Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVO Stock Alerts